NEW YORK MEDICAL COLLEGE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1860-01-01

Employees: 501

Market Cap: -

Website: http://www.nymc.edu

Clinical Trials

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

Phase 2

Recruiting

Conditions: Epstein-Barr Virus Infections
Primary Immune Deficiency Disorder

Interventions: Drug: cytotoxic t-lymphocytes

First Posted Date: 2017-08-30

Last Posted Date: 2024-11-14

Lead Sponsor: New York Medical College

Target Recruit Count: 20

Registration Number: NCT03266653

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Nationwide Children's Hosptial, Columbus, Ohio, United States

and more 5 locations

Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

Phase 2

Recruiting

Conditions: Adenovirus
Primary Immune Deficiency Disorder

Interventions: Drug: cytotoxic t-lymphocytes

First Posted Date: 2017-08-30

Last Posted Date: 2024-11-14

Lead Sponsor: New York Medical College

Target Recruit Count: 20

Registration Number: NCT03266627

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
Johns Hopkins, Baltimore, Maryland, United States

and more 7 locations

Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

Phase 2

Recruiting

Conditions: Primary Immune Deficiency Disorder
Cytomegalovirus Infections

Interventions: Drug: viral specific cytotoxic t-lymphocytes

First Posted Date: 2017-08-30

Last Posted Date: 2024-11-14

Lead Sponsor: New York Medical College

Target Recruit Count: 20

Registration Number: NCT03266640

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸
Children's Hospital of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 6 locations

Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS

Early Phase 1

Completed

Conditions: Postural Orthostatic Tachycardia Syndrome (POTS)
POTS
Orthostatic Intolerance

Interventions: Drug: Pyridostigmine
Drug: Digoxin
Drug: Placebo

First Posted Date: 2017-08-25

Last Posted Date: 2022-09-28

Lead Sponsor: New York Medical College

Target Recruit Count: 51

Registration Number: NCT03261570

Locations: 🇺🇸
New York Medical College/Bradhurst building, Hawthorne, New York, United States

Auto/Allo Tandem Transplant for Relapsed B-NHL

Completed

Conditions: Non Hodgkin Lymphoma

First Posted Date: 2017-07-02

Last Posted Date: 2023-11-07

Lead Sponsor: New York Medical College

Target Recruit Count: 12

Registration Number: NCT03205657

Reducing Orthostatic Intolerance With Oral Rehydration in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients

Phase 1

Conditions: Neurally Mediated Syncope (NMS)
Chronic Fatigue Syndrome
Systemic Exertion Intolerance Disease (SEID)
Myalgic Encephalomyelitis
Postural Tachycardia Syndrome (POTS)

Interventions: Drug: Normal Saline
Dietary Supplement: Oral Rehydration Solution

First Posted Date: 2016-08-03

Last Posted Date: 2021-06-10

Lead Sponsor: New York Medical College

Target Recruit Count: 45

Registration Number: NCT02854683

Locations: 🇺🇸
NewYork Medical College, Hawthorne, New York, United States

Prevention of Transfusion Related Acute Gut Injury (TRAGI) in Extremely Low Gestational Age Neonates (ELGANs) Using iNO

Phase 1

Conditions: Anemia

Interventions: Drug: Inhaled Nitric Oxide
Drug: Placebo

First Posted Date: 2016-08-01

Last Posted Date: 2019-04-24

Lead Sponsor: New York Medical College

Target Recruit Count: 50

Registration Number: NCT02851472

Locations: 🇺🇸
Stony Brook Children's Hospital, Stony Brook, New York, United States
🇺🇸
Maria Fareri Childrens Hospital, Valhalla, New York, United States
🇺🇸
East Carolina University, Greenville, North Carolina, United States

and more 1 locations

Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease

Phase 2

Recruiting

Conditions: Sickle Cell Disease

Interventions: Drug: Defibrotide

First Posted Date: 2016-02-05

Last Posted Date: 2024-07-31

Lead Sponsor: New York Medical College

Target Recruit Count: 40

Registration Number: NCT02675959

Locations: 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
University of Florida, Gainesville, Florida, United States

and more 1 locations

Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS)

Phase 2

Conditions: Vasovagal Syncope (VVS)
Postural Tachycardia Syndrome (POTS)
Fainting

Interventions: Drug: Northera (Droxidopa)
Drug: Placebo

First Posted Date: 2015-09-24

Last Posted Date: 2022-04-06

Lead Sponsor: New York Medical College

Target Recruit Count: 30

Registration Number: NCT02558972

Locations: 🇺🇸
New York Medical College/Bradhurst building, Hawthorne, New York, United States

Autologous Cord Blood and Human Placental Derived Stem Cells in Neonates With Severe Hypoxic-Ischemic Encephalopathy

Phase 2

Withdrawn

Conditions: Severe Hypoxic-ischemic Encephalopathy

Interventions: Drug: HPDSC
Drug: Cord blood

First Posted Date: 2015-05-06

Last Posted Date: 2021-02-23

Lead Sponsor: New York Medical College

Registration Number: NCT02434965

Locations: 🇺🇸
New York Medical College, Valhalla, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy